Results 11 to 20 of about 240,641 (402)

Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis [PDF]

open access: yes, 2014
Evidence suggests that advanced fibrosis, as determined by the noninvasive NAFLD fibrosis score (NFS), is a predictor of cardiovascular mortality in individuals with ultrasonography-diagnosed NAFLD. Whether the severity of histology (i.e., fibrosis stage)
Fiorentino, Tv   +5 more
core   +19 more sources

Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China.

open access: yesGastroenterology, 2023
BACKGROUND & AIMS This study aimed to estimate the prevalence of liver steatosis and fibrosis in the general population and populations with potential risk factors in China, so as to inform policies for the screening and management of fatty liver disease
S. Man   +9 more
semanticscholar   +1 more source

The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis

open access: yesNature Communications, 2023
Dietary lipids can affect metabolic health through gut microbiota-mediated mechanisms, but the influence of lipid-microbiota interaction on liver steatosis is largely unknown.
M. Schoeler   +20 more
semanticscholar   +1 more source

Association between SII and hepatic steatosis and liver fibrosis: A population-based study

open access: yesFrontiers in Immunology, 2022
Background The systemic immune-inflammation index (SII) is a novel marker of inflammation, and hepatic steatosis and fibrosis are associated with inflammation.
R. Xie   +7 more
semanticscholar   +1 more source

Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018

open access: yesFrontiers in Immunology, 2022
Background As a novel inflammatory marker, Systemic Immune-Inflammation Index (SII) has not been studied with hepatic steatosis. The aim of this study was to investigate the possible relationship between SII and hepatic steatosis.
Yancheng Song   +5 more
semanticscholar   +1 more source

Serum cadmium is associated with hepatic steatosis and fibrosis

open access: yesMedicine, 2022
Although cadmium (Cd) is correlated with elevated levels of hepatic amino transferases, its influence on the degree of liver steatosis and fibrosis are unknown yet.
S. Han   +4 more
semanticscholar   +1 more source

New Perspectives of S-Adenosylmethionine (SAMe) Applications to Attenuate Fatty Acid-Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells

open access: yesMolecules, 2020
S-adenosylmethionine (SAMe) is an endogenous methyl donor derived from ATP and methionine that has pleiotropic functions. Most SAMe is synthetized and consumed in the liver, where it acts as the main methylating agent and in protection against the free ...
Laura Vergani   +5 more
doaj   +1 more source

Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease

open access: yesAntioxidants, 2020
Background: Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation, especially triglycerides, in hepatocytes. If the pathology is not properly treated, it can progress to nonalcoholic steatohepatitis (NASH) and continue ...
Margalida Monserrat-Mesquida   +11 more
doaj   +1 more source

Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. [PDF]

open access: yes, 2017
This study aims to uncover how specific bacteria and bile acids (BAs) contribute to steatosis induced by diet and farnesoid X receptor (FXR) deficiency in both genders.
French, Samuel W   +8 more
core   +1 more source

Animal models of NASH: getting both pathology and metabolic context right [PDF]

open access: yes, 2015
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease.
Larter, Claire Z., Yeh, Matthew M.
core   +1 more source

Home - About - Disclaimer - Privacy